PMID- 22483478
OWN - NLM
STAT- MEDLINE
DCOM- 20120730
LR  - 20120409
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 44
IP  - 3
DP  - 2012 Apr
TI  - Hepatic stellate cells attenuate the immune response in renal transplant 
      recipients with chronic hepatitis.
PG  - 725-9
LID - 10.1016/j.transproceed.2011.11.049 [doi]
AB  - BACKGROUND: Chronic viral hepatitis is no longer a contraindication to renal 
      transplantation (RT), owing to our better understanding of the hepatitis virus. 
      Hepatitis patients may receive RT depending on their response to viral therapy. 
      RT patients with hepatitis generally do not have an inferior prognosis compared 
      with RT patients without the disease. Hepatic stellate cells (HSCs) are activated 
      during chronic viral hepatitis. The role of HSCs in immunoregulatory effects in 
      RT recipients has not been fully elucidated. METHODS: We recruited 22 RT 
      recipients with chronic viral hepatitis, who composed the chronic liver disease 
      (CLD) group, and 25 disease-free recipients, who served as the control group. We 
      retrieved their clinical data and collected serum to measure cytokine levels. To 
      investigate the immunoregulatory effect of HSCs, we cocultured HSCs with 
      allogeneic antigen-presenting cell-activated T cells (mixed lymphocyte reaction 
      [MLR]) in Transwell plates. RESULTS: The liver biopsy disclosed activation HSCs 
      in 1 chronic hepatitis C virus recipient without treatment. Serum monocyte 
      chemoattractant protein-1 (MCP-1) levels in the CLD group (41.6 +/- 27.4 pg/mL) 
      were significantly higher than those in the control group (28.1 +/- 12.8 pg/mL; P = 
      .008). There were similar levels of transforming growth factor-beta1 (TGF-beta1). In 
      allogeneic MLR, HSCs inhibited T-cell activation through the soluble factors in 
      the Transwell assays. There was a high level of MCP-1 in the supernates of the 
      HSC group in the allogeneic MLR, but TGF-beta1 was lower in HSCs cocultured with MLR 
      than in the control group, except in the early period. CONCLUSIONS: HSCs may play 
      an immunoregulatory role in chronic viral hepatitis recipients to minimize the 
      effect of immunosuppressants without affecting rejection. The immunomodulatory 
      effects may be attributed to soluble factors in HSCs.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Su, Y-H
AU  - Su YH
AD  - Department of Life Science, Tunghai University, Taichung, Taiwan.
FAU - Shu, K-H
AU  - Shu KH
FAU - Hu, C
AU  - Hu C
FAU - Cheng, C-H
AU  - Cheng CH
FAU - Wu, M-J
AU  - Wu MJ
FAU - Yu, T-M
AU  - Yu TM
FAU - Chuang, Y-W
AU  - Chuang YW
FAU - Huang, S-T
AU  - Huang ST
FAU - Chen, C-H
AU  - Chen CH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Chemokine CCL2/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Hepatic Stellate Cells/*immunology
MH  - Hepatitis C, Chronic/*immunology
MH  - Humans
MH  - Kidney Transplantation/*immunology
MH  - Lymphocyte Culture Test, Mixed
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Middle Aged
EDAT- 2012/04/10 06:00
MHDA- 2012/07/31 06:00
CRDT- 2012/04/10 06:00
PHST- 2012/04/10 06:00 [entrez]
PHST- 2012/04/10 06:00 [pubmed]
PHST- 2012/07/31 06:00 [medline]
AID - S0041-1345(11)01646-0 [pii]
AID - 10.1016/j.transproceed.2011.11.049 [doi]
PST - ppublish
SO  - Transplant Proc. 2012 Apr;44(3):725-9. doi: 10.1016/j.transproceed.2011.11.049.